Ask us a question 520 547-3440 info@c-path.org

Subscribe

Home
About
Programs
Sharing Knowledge that Leads to Innovation
ACTIVE CONSORTIA / PROGRAMS

BmDR

Biomarker Data Repository

CPAD

Critical Path For Alzheimer’s Disease

CPP

Critical Path for Parkinson’s

CP-SCD

Critical Path for Sickle Cell Disease

CPTR

Critical Path to TB Drug Regimens

CPTA

Critical Path to Therapeutics for the Ataxias

CDRC

CURE Drug Repurposing Collaboratory

DCC

Data Collaboration Center

D-RSC

Duchenne Regulatory Science Consortium

eCOA Consortium

Electronic Patient-Reported Outcome Consortium

FA-ICD

Friedreich’s Ataxia Integrated Clinical Database

HD-RSC

Huntington’s Disease Regulatory Science Consortium

INC

International Neonatal Consortium

MSOAC

Multiple Sclerosis Outcome Assessments Consortium

PRO Consortium

Patient-Reported
Outcome Consortium

PKDOC

Polycystic Kidney Disease Outcomes Consortium

PredicTox KE

PredicTox Knowledge Environment

PSTC

Predictive Safety Testing Consortium

QuantMed

Quantitative Medicine Program

RDCA-DAP

Rare Disease Cures Accelerator-Data and Analytics Platform

TB-PACTS

TB-Platform for Aggregation of Clinical TB Studies

TTC

Transplant Therapeutics Consortium

TOMI-T1D

Trial Outcome Markers Initiative in T1D Consortium

T1D

Type 1 Diabetes Consortium

Completed Consortia

CFAST

Coalition for Accelerating Standards & Therapies

PTC

Pediatric Trials Consortium
Core Competencies
- Evidentiary Considerations
Impact
- Impact Stories
- Successes
News & Events
- Events
- News
- Videos
- Publications
- Presentations
- Press Releases
Education
Contact
Donate

News

Home>News & Events>Pharmaceutical Industry Members>Sequella

News

May 31, 2013 PRINT PDF

Sequella

View Now | October 28-29 | International Neonatal Consortium 2020 Virtual Workshop
2021 PKD Regulatory Summit
VIEW NOW: COVID-19 Mitigation Strategies in Pediatric Rare Disease Clinical Trials Virtual Workshop
Current state of cardiac troponin testing in Duchenne muscular dystrophy cardiomyopathy: review and recommendations from the Parent Project Muscular Dystrophy expert panel
Qualification of translational safety biomarkers.

FAQ
Annual Reports
Employment
Contact
Terms of Use
Policies
GDPR SCCs
Privacy Policy
Explore C-Path
Donate

C-Path Main Office 1730 E. River Rd., #200
Tucson, AZ. 85718
Tel: 520-547-3440
Fax: 520-547-3456 C-Path Global Ltd. 33 Sir John Rogerson’s
Dublin 2, Ireland

Ask us a question Tel: 520-547¬3440
Email: info@c-path.org Subscribe

x

News

News

Sequella

Related Posts